Effects of long-term octreotide treatment on the response of portal-systemic collaterals to vasopressin in portal hypertensive rats

European Journal of Clinical Investigation

Volumn 32, Issue 5, 2002, Pages 316-321

  Wang, Sun Sang ^a   Chan, C C ^a   Lee, F Y ^a   Chang, F Y ^a   Lin, H C ^a   Chen, C T ^a   Huang, H C ^a   Tai, C C ^a   Lai, I N ^a   Lee, S D ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Octreotide; Portal hypertension; Portal systemic collaterals; Vasopressin

Indexed keywords

OCTREOTIDE; PLACEBO; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HEMODYNAMICS; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERFUSION PRESSURE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION; VASOCONSTRICTION; VEIN LIGATION;

ANIMALS; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HYPERTENSION, PORTAL; LINEAR MODELS; MALE; OCTREOTIDE; PORTAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 0037003189     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00987.x     Document Type: Article

References (27)

1. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
2. Westaby D, Gimson A, Hayes PC, Williams R. Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut 1988;29:327-77.
3. Tsai YT, Lay CS, Lai KH, Ng WW, Yeh YS, Chiang TT et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986;6:406-9.
4. Gimson AES, Westaby D, Hegert J et al. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986;6:410-3.
5. Bosch J, Groszmann RJ, Garcia-Pagan JC, Teres J, Garcia-Tsao G, Navasa M et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo controlled clinical trial. Hepatology 1989;10:962-8.
6. Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology 1996;23:1218-23.
7. Huang YT, Tsai JF, Liu TB, Hong CY, Yang MC, Lin HC. Chronic administration of octreotide increase vascular responsiveness in rats with portal hypertension. Clin Sci 1996;91:601-6.
8. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630-5.
9. Chojker M, Groszmann RJ. Measuement of portal-systemic shunting in the rat by using γ-labeled microsphere. Am J Phsyiol 1981;240:G371-G375.
10. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992;263:G544-G550.
11. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane 'lung' for small organ perfusion. J Lipid Res 1974;15:182-6.
12. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N-omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
13. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G57.
14. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-9.
15. Kiel JW, Pitts V, Benoit JN, Granger DN, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985;248:G192-G195.
16. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992;262:G996-G1001.
17. Weigert AL, Martin PY, Niederberger M, Higa EM, McMurtry IF, Gines P et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995;22:1856-62.
18. Lin HC, Yang MCM, Hou MC, Li SM, Huang YT, Yu PC et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996;23:537-43.
19. + retention in portal hypertensive rats. Gastroenterology 1993;104:575-9.
20. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618-G625.
21. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001;120:975-83.
22. Sata T, Linden J, Liu LW, Kubota E, Said SI. Vasoactive intestinal peptide evokes endothelium-dependent relaxation and cyclic AMP accumulation in rat aorta. Peptide 1988;9:853-8.
23. Toda N, Okamura T. Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries. Am J Physiol 1989;257:H988-H995.
24. Pernow J. Actions of constrictor (NPY and endothelin) and dilator (substance P, CGRP and VIP) peptides on pig splenic and human skeletal muscle arteries: involvement of the endothelium. Br J Pharmacol 1989;97:983-9.
25. Sumanovski LT, Battegay E, Stumm M, van der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999;29:1044-9.
26. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski. J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000;268:567-71.
27. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997;3:265-72.